Following the Departments of Labor, Treasury, and Health and Human Services’ (collectively, the “Departments”) issuance of a final rule for the No Surprises Act (which we previously reported on here), the Fifth Circuit recently struck down the government’s methodology for determining qualifying payment amounts (“QPA”) in a major win for providers.

In July 2021, the Departments promulgated an interim-final rule (the “July Rule”) establishing the methodology for calculating the QPA. Providers challenged the methodology on three grounds, arguing that the Departments’ rules artificially depressed QPAs and unfairly favored insurers.

In its August 11, 2026 en banc decision, the Fifth Circuit explained that the QPA is the “median of the total maximum rates in an insurer’s contract for an item or service that a provider provides and furnishes.” The QPA is an important figure in the NSA’s independent dispute resolution (“IDR”) process, which adjudicates how much an insurer owes to an out-of-network provider. The issue before the Fifth Circuit was whether insurers could include certain rates and payments in their QPA calculations, including “ghost rates” (i.e., rates appearing in contracts between insurers and providers for items and services the providers do not actually provide), as well as bonus and incentive payments.

Ghost Rates

The most significant portion of the Fifth Circuit’s decision was its exclusion of ghost rates from QPA calculations. Insurers are incentivized to keep QPAs low to minimize cost-sharing obligations. The Fifth Circuit emphasized that these artificially low QPAs are leading to more favorable IDR rulings for providers, noting that providers have prevailed in over 80% of arbitrations and that arbitrators selected a reimbursement rate higher than the QPA in 85% of arbitrations.

Under the July Rule, insurers were directed to include “each contracted rate” appearing in their contracts with providers. When insurers and providers negotiate contracts, insurers typically present form contracts with default fee schedules covering all services. Providers generally negotiate rates only for services they actually provide, leaving unnegotiated rates for services they never perform untouched. These ghost rates can be as low as $0 or $1. Under the government’s methodology, issued in August 2022 guidance, the Departments instructed insurers to exclude $0 ghost rates from their QPA calculations—but any non-zero ghost rate was fair to include.

The Fifth Circuit held that the inclusion of ghost rates was contradicted by the plain text of the NSA, which limits the QPA to an “item or service that is provided by a provider” and “provided in the geographic region in which the item or service is furnished.”[1] The Fifth Circuit reasoned that, “[i]f the provider submitted no claims and received no payments for a particular item or service . . . then that item or service was neither ‘provided by a provider’ nor ‘furnished’.”  Therefore, the NSA precludes the inclusion of ghost rates in QPA calculations, as they are rates for services that are neither provided nor furnished.

Bonus and Incentive Payments

The Fifth Circuit also ruled that the July Rule’s exclusion of “risk sharing, bonus, penalty, or other incentive-based or retrospective payments” from QPA calculations was contrary to law. The NSA requires that each contracted rate reflect the “total maximum payment” for an item or service. The Fifth Circuit explained that “total” means the entire amount and “maximum” means the highest possible amount. Therefore, if payments come in the form of bonuses or incentives, they must still be included in the QPA calculation.

Single-Case Agreements

The Fifth Circuit agreed with the Departments that one-off, single-case agreements, which are particularly prevalent in the air ambulance industry, are properly excluded from “contracted rates” used to calculate the QPA. The Fifth Circuit reasoned that “the word ‘rate’ connotes a per-unit price for multiple units,” not one-off transactions. Additionally, single-case agreements are “not rates ‘recognized’ ‘under’ an insurer’s plan or coverage” because they arise in emergency situations when insurers pay out-of-network providers at exceedingly high rates apart from any generally applicable health plan.

Next Steps

Based on the Fifth Circuit’s ruling, insurers can expect much higher calculated QPAs when engaging in IDR under the NSA due to the exclusion of ghost rates and bonus and incentive payments. Providers and payors should monitor agency guidance for additional developments on QPA calculations.

[1] See 42 U.S.C. § 300gg-111(a)(3)(E)(i)(I).

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Vinay Kohli Vinay Kohli

Vinay Kohli is a healthcare industry lawyer.  Recognized for his focus and commitment to the healthcare industry, a wide range of healthcare businesses use Vinay as an outside general counsel to guide them on strategic planning, compliance matters, operational questions, and reimbursement concerns. …

Vinay Kohli is a healthcare industry lawyer.  Recognized for his focus and commitment to the healthcare industry, a wide range of healthcare businesses use Vinay as an outside general counsel to guide them on strategic planning, compliance matters, operational questions, and reimbursement concerns.  He provides regulatory, compliance, and reimbursement advice on topics that range from venture formation, technology implementation, and risk management to day-to-day contract negotiations.

Vinay’s background is unique in that he is also a seasoned trial lawyer.  He is able to combine his regulatory expertise with a trial lawyer skillset for jury trials, bench trials, and arbitrations arising in the healthcare arena—he represents hospital systems, physician practices, providers of post-acute care services, as well as healthcare technology and revenue cycle management companies. He defends health care fraud and abuse litigation, prosecutes managed care disputes against large national payors, and handles government investigations.  And clients frequently call upon Vinay to serve as lead trial counsel in commercial litigation disputes that span the gamut from breach of contract and trade secret misappropriation to unfair business practices and breach of fiduciary claims.

Vinay received his B.B.A., magna cum laude, M.A., and J.D. from the University of Texas at Austin in 2005, 2006, and 2009 respectively.

Prior to joining Proskauer, Vinay was a partner in the Healthcare group at King & Spalding.

Photo of Devin Cohen Devin Cohen

Devin Cohen is a partner in the Corporate Department and a member of Proskauer’s Health Care Group.

Devin counsels leading health care organizations and private equity sponsors operating at the cutting edge of the industry on their most important transactional and regulatory matters.

Devin Cohen is a partner in the Corporate Department and a member of Proskauer’s Health Care Group.

Devin counsels leading health care organizations and private equity sponsors operating at the cutting edge of the industry on their most important transactional and regulatory matters. He has a deep understanding of both deal mechanics and the evolving regulatory landscapes in the areas of strategic investment, vertical integration, insurance and brokerage, as well as research.

Over the course of his career, Devin has advised a wide range of health care organizations and investors on value-based care arrangements and initiatives, and routinely advises insurers and providers to structure collaborative care models and Medicare Advantage. In addition, Devin has worked with clients on matters related to pharmaceutical and medical device research and development and clinical trials, including fraud and abuse considerations, human subject protections requirements, animal welfare standards, sponsored and investigator-initiated research negotiations, and compliance monitoring.

Clients value Devin’s responsiveness, as well as his ability to cut through complexity to provide clear, actionable guidance. They also appreciate the strong people skills he brings to the table, which are particularly helpful in negotiations.

Devin’s passion for health care extends to his community service and pro bono efforts in the Boston area. He works with Heading Home and other non-profits providing shelter to those in need throughout the Commonwealth of Massachusetts, among others.

Devin joins Proskauer from Ropes & Gray LLP where he was a partner in the firm’s Health Care practice.

Experience

Devin regularly works with a wide range of health care organizations — including physician groups, academic medical centers, clinical networks, hospitals, dental and management services organizations, insurers, brokers/agents, pharmaceutical and medical device manufacturers, and provider organizations — as well as industry investors, across areas such as:

Health care transactions and investments

  • Provide transactional and regulatory counsel to providers and investors. Examples include:
  • Assisted multiple regional health plans in their mergers and acquisitions of new plans to expand insurance product offerings.
  • Advised a private equity firm on its investment in an online insurance brokerage platform.
  • Counsel investors on emerging state health care transaction laws, corporate practice of medicine, and MSO/DSO structuring.
  • Advise multiple private sponsors on CRO and SMO investments

Value-based care arrangements

  • Counsel a wide range of providers, payors, practice management organizations, vendors and industry investors in the areas of Medicare Advantage, CMMI program participation, state risk-bearing implications and insurance requirements.
  • Advise on strategic partnerships and joint ventures, including innovative collaborations aimed at expanding access to value-based primary care for Medicare beneficiaries.

Regulatory and compliance

  • Routinely counsel Medicare Advantage Organizations, FDRs and program vendors on Medicare Advantage regulatory and contracting standards.
  • Advise investors and brokers/agencies on emerging Medicare requirements, including emerging standards related to sales commissions payments.
  • Advise medical device and pharmaceutical manufacturers on regulatory standards related to customer and patient interactions, marketing and clinician education standards, industry and jointly sponsored CME, patient assistance programs, and related compliance program requirements.

Clinical research and related activities

  • Regularly provide guidance on drug and drug component development/commercialization considerations for sites, investigators and sponsors.
  • Routinely advise institutional and start-up manufacturers, as well as CROs and trial sites, on cutting-edge clinical trial contracting negotiations.
  • Provide counsel on research affiliation agreements, including advising a large academic medical center on developing and implementing its research affiliation agreement with a local pediatric health network.
  • Conduct regulatory diligence for private equity clients regarding their planned investments in companies that participate in the clinical research enterprise.
  • Advise academic medical centers on research misconduct matters.
Photo of Matthew J. Westbrook Matthew J. Westbrook

Matt Westbrook is a senior counsel in the Corporate Department and a member of the Health Care Group. His practice focuses on providing regulatory compliance advice for the Firm’s health care clients, including service providers, health plans, operators, investors, and lenders, among others.

Matt Westbrook is a senior counsel in the Corporate Department and a member of the Health Care Group. His practice focuses on providing regulatory compliance advice for the Firm’s health care clients, including service providers, health plans, operators, investors, and lenders, among others. Matt specifically provides advice on fraud and abuse matters arising under the Federal False Claims Act (FCA), Civil Monetary Penalties Law, Federal Anti-Kickback Statute (AKS), and Physician Self-Referral Law (Stark Law), as well as on the regulations promulgated by the Drug Enforcement Administration (DEA) and the Department of Health and Human Services, including the Office of Inspector General (OIG), Centers for Medicare & Medicaid Services (CMS), and Food and Drug Administration (FDA).

Before joining the Firm, Matt served as senior counsel in OIG’s Administrative and Civil Remedies Branch. At OIG, Matt was responsible for determining whether to impose administrative sanctions, including civil money penalties and Federal health care program exclusions, against health care providers and suppliers, and whether to impose civil money penalties on hospitals and physicians in connection with matters referred to CMS under the Emergency Medical Treatment and Labor Act (EMTALA). During his tenure, Matt also litigated exclusion appeals before administrative law judges and appellate panels of the Departmental Appeals Board; advised United States Attorney’s Offices on exclusions appealed to Federal district courts; resolved voluntary self-disclosures submitted by providers and grant and contract recipients; and participated in the negotiations and settlements of FCA matters by the Department of Justice involving the AKS, Stark Law, CMS reimbursement issues, and DEA and FDA compliance issues. In connection with certain FCA resolutions, Matt also negotiated and monitored corporate integrity agreements.

On the Florida junior circuit and in college, Matt was a competitive tennis player. Matt played on the varsity team and was captain his senior year at Rhodes College, earning ITA Division III and SCAC All-Academic Honor Roll awards his sophomore, junior, and senior years. Matt is an active member of the American Health Law Association (AHLA) and currently serves as a Vice Chair of AHLA’s Fraud and Abuse Practice Group.

Articles:

Matthew J. Westbrook and David M. Blank, “Using OIG’s Cross-Component Audit and Enforcement Data to Strengthen Your Compliance Program,” Compliance Today (February 2024).

Ed Kornreich, Matthew Westbrook, and Angela Gichinga, “Bracing for the Impact of the No Surprises Act,” Westlaw Today (June 16, 2022).

Presentations:

Bill Mathias and Matt Westbrook, “‘Lightning Round’:  A Fraud & Abuse Due Diligence Game Show,” American Health Law Association (Health Care Transactions Conference, May 5–6, 2025).

Matthew J. Westbrook and David M. Blank, “Recent Trends in CMPL Enforcement, American Health Law Association (Webinar, May 24, 2023).